XtalPi Holdings Ltd. has announced a new partnership with DoveTree LLC, a company founded by Professor Gregory Verdine. This collaboration involves XtalPi utilizing its end-to-end AI drug discovery platform, which integrates "AI + robotics" technology, to develop small molecule and antibody drug candidates targeting tumors, autoimmune diseases, and neurological conditions. As part of the agreement, XtalPi will receive an initial payment of US$51 million, followed by an additional US$49 million within 180 days post-signing of the Definitive Agreement. The partnership also includes potential milestone and sales payments, reaching billions, and royalties based on a single-digit percentage. This collaboration aims to leverage XtalPi's technological strengths to bring breakthrough therapies to patients globally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.